Navigation Links
The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
Date:9/13/2007

Study results outline dabigatran etexilate as potential thromboprophylaxis

therapy for patients undergoing total hip replacement surgery

RIDGEFIELD, Conn., Sept. 13 /PRNewswire/ -- Boehringer Ingelheim today announced that the September 15 issue of The Lancet will publish results from the RE-NOVATE study, which investigated dabigatran etexilate as a potential therapy for patients undergoing total hip replacement surgery(1). The results from this study demonstrate that both doses (220mg and 150mg) of the oral direct thrombin inhibitor, dabigatran etexilate, administered for a median of 33 days, were non-inferior to injectable enoxaparin in reducing the risk of venous thromboembolism (VTE) after total hip replacement surgery with similar safety.

The primary endpoint of this trial was a composite consisting of total venous thromboembolic events and all-cause mortality during treatment, which occurred in 6.0% of the 220mg group and 8.6% of the 150mg group taking dabigatran etexilate, versus 6.7% of the enoxaparin group. Importantly, a pre-specified secondary outcome of major venous thromboembolism and venous thromboembolism-related mortality was also similar between groups, occurring in 3.1% of the 220mg group and 4.3% of the 150mg group taking dabigatran etexilate, versus 3.9% of the enoxaparin group.

Anticoagulation-related bleeding is the primary safety concern during hip replacement surgery, since major bleeding into the replaced joint can have a detrimental impact on clinical outcome(2). Generally, few major bleeding events were reported, occurring at 2.0% in the 220mg group and 1.3% in the 150mg group for dabigatran etexilate, versus 1.6% in the enoxaparin group. Notably about half of all major bleeding events started after surgery and before the first dose of dabigatran etexilate. There were no major bleeding events reported after hospital discharge in the dabigatran etexilate groups.

Data from frequent liver function monitor
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
2. Data Published in The Lancet Show Gardasil was 100 Percent Effective in Preventing High-Grade Vulvar and Vaginal Lesions Caused by HPV Types 16 and 18
3. The Lancet Publishes PREVAIL Study Results Showing Lovenox Superiority Over Unfractionated Heparin for Reducing the Risk of Venous ThromboEmbolism in Patients With Acute Ischemic Stroke
4. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
5. Arrowhead Subsidiary, Insert, Publishes Interim Phase I Data from Human Clinical Trials for New Cancer Drug
6. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
7. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
8. Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
9. Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
10. Medical Journal Publishes First Large-Scale Survey Revealing Experiences of IPF Patients
11. Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on Targeted, Systemic Delivery of siRNA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... SANTA CLARA, Calif. , Oct. 22, 2014 /PRNewswire/ ... today announced the introduction of the cQUB™-1 (cQuest Ultrasound ... cQUB white-label ultrasound systems designed and manufactured by Cephasonics ... brand name and model number. Cephasonics will be showcasing ... 2014 being held this week in Chongqing, ...
(Date:10/22/2014)... , Oct. 22, 2014  Quest Diagnostics (NYSE: ... information services, today announced that its Board of Directors ... a director, effective December 1, 2014. Including Dr. Leiden, ... is the Chairman, President and CEO of Vertex Pharmaceuticals. ... scientific and commercial experience in the pharmaceutical and biotechnology ...
(Date:10/22/2014)... Calif. , Oct 22, 2014 Antigen ... Irvine, California , announced the receipt of ... Business Innovation Research award (SBIR) from the National Institute of Dental ... fund the development of a Pan-HIV Protein Microarray Chip, ... HIV-1 and HIV-2 subtypes and aid in the development ...
Breaking Medicine Technology:Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 3Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 2Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 3Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2
... Oct. 13 The Care Continuum Alliance ... Award for the "Greatest Impact on Health" at ...  The ALL/PHASE protocol, which utilizes low-cost and generic medications ... successfully implemented in Kaiser Permanente communities, including those served ...
... Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna -- OOSTERHOUT, Netherlands, Oct. 13 ... ... (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
Cached Medicine Technology:Kaiser Permanente's ALL/PHASE Initiative Wins 2010 Care Continuum Alliance Quality Impact Award for Greatest Impact on Health 2Kaiser Permanente's ALL/PHASE Initiative Wins 2010 Care Continuum Alliance Quality Impact Award for Greatest Impact on Health 3Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna 2Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna 3Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna 4Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna 5Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna 6Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna 7Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna 8Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna 9
(Date:10/25/2014)... Background: , In 1998 Bob Savage founded the ... in the field of establishing recovery community organizations. Bob ... when he retired, he set out to answer a couple ... , 1. Where are the people in recovery ... 2. Can the recovery community be organized to advocate for ...
(Date:10/25/2014)... The Wehrman Collaborative, LLC ... for disabled users by disabled users, has granted ... Mackin Educational Resources of Burnsville, Minnesota, for their ... to the Minnesota Alliance for Patient Safety of ... website. Both organizations have met WeCo’s ...
(Date:10/25/2014)... QueenBeeTickets.com has a variety of tickets for ... prices. Bob Seger & The Silver Bullet Band tickets ... are going on sale October 25 and are expected ... browse the selection of tickets for Bob Seger & ... singer is touring North America beginning next month, and ...
(Date:10/25/2014)... York (PRWEB) October 25, 2014 ... lawsuits ( http://www.vaginalmeshlawsuit2015.com/ ) filed against Boston ... in U.S. District Court, Southern District of West ... Judgment on Punitive Damages in a group of ... a ruling issued on October 21st, U.S. District ...
(Date:10/25/2014)... Limbkeepers® announced today that they will be featured ... Jr, airing 1st QTR 2015 via Discovery Channel. Dates ... will focus on Limbkeepers® non compression knit sleeves, a ... arms, hands, and legs from abrasion, skin tears and ... help reduce injuries, allow for continued daily activities, and ...
Breaking Medicine News(10 mins):Health News:CCAR Accepting Nominations for the Bob Savage Recovery Advocate of the Year Award 2Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 2Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 3Health News:QueenBeeTickets.com Features Bob Seger & The Silver Bullet Band Tickets for Charleston Civic Center, Huntington Center, and Nationwide Arena at Reduced Prices 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 4Health News:Upcoming Episode of Innovations with Ed Begley, Jr. to Feature Limbkeepers® 2
... It was a "common sense" decision to start the ... of the stroke belt. , "We wanted to give better ... of the Department of Neurology at the Medical College of ... 2000 and Hess and his colleagues were frustrated that nearly ...
... Researchers at UT Southwestern Medical Center have developed what ... new imaging technique to diagnose brain tumors. The unique test ... are located in areas of the brain too dangerous to ... a definitive diagnosis of cancer based on imaging of a ...
... , THURSDAY, Jan. 26 (HealthDay News) -- Popular cholesterol-lowering statins may ... a new study shows. Hepatitis B, an inflammation of the liver ... causes of liver cancer. This is not the first ... Other studies have hinted that these drugs may play a role ...
... (HealthDay News) -- Positive reinforcement, such as receiving small, ... seems to help patients with high blood pressure take ... of black Americans. The findings are significant because ... and death, the researchers from the Center for Healthful ...
... lung clearance index (LCI) is a sensitive non-invasive marker of ... according to a new study from Australian researchers. "We ... especially in the presence of airway inflammation and Pseudomonas aeruginosa," ... the Sydney Children,s Hospital. "LCI may not only be a ...
... Reporter , THURSDAY, Jan. 26 (HealthDay News) -- The rate ... dramatic upturn since 2004, reversing a trend of decline throughout ... place outside of the traditional hospital setting increased 29 percent ... to 0.72 percent -- almost 30,000 births -- according to ...
Cached Medicine News:Health News:Georgia Bio honors biotech company that enables stroke care 2Health News:Georgia Bio honors biotech company that enables stroke care 3Health News:Diagnostic brain tumor test could revolutionize care of patients 2Health News:Statins May Stave Off Liver Cancer in People With Hepatitis B 2Health News:Positive Reinforcement May Help Patients Take Their Meds 2Health News:Early cystic fibrosis lung disease detected by bronchoalveolar lavage and lung clearance index 2Health News:More U.S. Babies Born at Home: Report 2Health News:More U.S. Babies Born at Home: Report 3
... The Aisys Carestation helps you deliver unmatched ... Aisys Carestation is the most complete anesthesia ... point of need - at your fingertips., ... our industry-leading Datex-Ohmeda legacy of anesthesia delivery ...
... Mesh LP is a super-light polypropylene mesh ... body reaction is reduced considerably. Optilene Mesh ... all open hernia repair procedures. It perfectly ... flexibility Optilene Mesh LP adapts to the ...
... Optilene Mesh Elastic is a lightweight and ... elasticity the mesh is able to adapt to ... The new honeycomb like structure with the large ... elastic scar. The mesh is ideal for incisional ...
... LP is a lightweight polypropylene mesh ... considerably reduced,foreign body reaction. The softer, ... It perfectly conforms to,anatomical structures. Due ... LP adapts to the movements of ...
Medicine Products: